NCT06593197View on ClinicalTrials.gov

Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 30, 2027

Conditions
Vitiligo
Interventions
COMBINATION_PRODUCT

Apremilast with NB-UVB

Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months

DEVICE

NB-UVB

NBUVB only will be given twice per week for 8 months

Trial Locations (1)

Unknown

Dow International Medical College , DUHS, Karachi

All Listed Sponsors
lead

Dow University of Health Sciences

OTHER

NCT06593197 - Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients | Biotech Hunter | Biotech Hunter